Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | PCSK9 | Q8NBP7 | 4/20 | 0.37 |
| ▸ | XDH | P47989 | 2/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.36 |
| ▸ | PNP | P00491 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21393418 | 0.85 | SMN1; SMN2 (0.40) | HSD17B10SMN1; SMN2ALDH1A1CYP2C19XDH | |
| SCHEMBL21393579 | 0.84 | LMNA (0.44) | KDM4ESMN1; SMN2CYP2C19LMNAHTT | |
| SCHEMBL26155903 | 0.81 | TRPA1 (0.38) | TP53HSD17B10ALDH1A1XDHPOLB | |
| SCHEMBL21393574 | 0.80 | POLB (0.41) | KDM4EHSD17B10SMN1; SMN2ALDH1A1XDH | |
| SCHEMBL21393414 | 0.79 | JAK3 (0.33) | ALDH1A1XDHPOLB | |
| SCHEMBL26155899 | 0.78 | GDA (0.48) | KDM4EALDH1A1POLBTRPA1 | |
| SCHEMBL26155912 | 0.75 | RECQL (0.46) | TP53KDM4EHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL21363370 | 0.73 | TRPA1 (0.42) | TP53KDM4EHSD17B10SMN1; SMN2ALDH1A1 | |
| SCHEMBL21363641 | 0.71 | POLB (0.44) | KDM4EHSD17B10ALDH1A1CYP2C19HTT | |
| SCHEMBL21393345 | 0.71 | TRPA1 (0.39) | SMN1; SMN2ALDH1A1XDHLMNAPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | GENENTECH, INC. (US) | 2023-05-23 | — | — | US | disclosed |
| WO-2019182925-A1 | OXADIAZOLE TRANSIENT RECEPTOR POTENTIAL CHANNEL INHIBITORS | GENENTECH, INC. (US) | 2019-09-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11655245-B2 | Oxadiazole transient receptor potential channel inhibitors | TRPA1, TRPV1, P2RX3 | CYP3A4 843/4885TP53 3670/4885KDM4E 3914/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.